Symbols / MTVA Stock $1.61 +1.26% MetaVia Inc.

Healthcare • Biotechnology • United States • NCM
MTVA (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Hyung Heon Kim
Exch · Country NCM · United States
Market Cap 8.31M
Enterprise Value -2.01M
Income -12.97M
Sales —
FCF (ttm) -11.28M
Book/sh 2.31
Cash/sh 2.02
Employees 8
Insider 10d —
IPO Aug 05, 2016
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E —
PEG —
P/S —
P/B 0.70
P/C —
EV/EBITDA 0.15
EV/Sales —
Quick Ratio 1.82
Current Ratio 1.93
Debt/Eq 3.94
LT Debt/Eq —
EPS (ttm) -7.35
EPS next Y —
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2025-11-06
Earnings (prior) 2025-11-06
ROA -62.58%
ROE -195.61%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 5.16M
Shs Float 3.34M
Insider Own 35.00%
Instit Own 3.09%
Short Float 1.94%
Short Ratio 0.37
Short Interest 64.28K
52W High 19.03
vs 52W High -91.54%
52W Low 1.17
vs 52W Low 37.61%
Beta 0.34
Impl. Vol. —
Rel Volume 0.46
Avg Volume 216.20K
Volume 99.70K
Target (mean) $19.33
Tgt Median $20.00
Tgt Low $8.00
Tgt High $30.00
# Analysts 3
Recom None
Prev Close $1.59
Price $1.61
Change 1.26%
About

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. Its therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. The company has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$19.33
Mean price target
2. Current target
$1.61
Latest analyst target
3. DCF / Fair value
$-39.31
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.61
Low
$8.00
High
$30.00
Mean
$19.33

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-27 main HC Wainwright & Co. Buy → Buy $20
2026-01-06 main HC Wainwright & Co. Buy → Buy $40
2025-05-19 main Maxim Group Buy → Buy $3
2025-04-16 reit HC Wainwright & Co. Buy → Buy $12
2025-03-21 reit HC Wainwright & Co. Buy → Buy $12
2024-12-30 init HC Wainwright & Co. — → Buy $12
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-01-23 KIM HYUNG HEON Chief Executive Officer — 32,000 $0.00 $0
2026-01-23 WOODWORTH MARSHALL H Chief Financial Officer — 28,000 $0.00 $0
2025-08-12 WOODWORTH MARSHALL H Chief Financial Officer — 14,200 $0.00 $0
2025-06-30 SALSBURY MICHAEL Director — 28,147 $0.00 $0
2025-06-30 STRICKLAND DAVID GORDON Director — 28,147 $0.00 $0
2025-06-30 KOVEN ANDREW IAN Director — 28,147 $0.00 $0
2025-06-30 GLICKMAN MARK A Director — 28,147 $0.00 $0
2025-06-30 GROVES JASON L Director — 28,147 $0.00 $0
2025-06-30 TURSI JAMES PATRICK Director — 28,147 $0.00 $0
2025-06-04 WOODWORTH MARSHALL H Chief Financial Officer — 14,200 $0.70 $9,940
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
13.71
-52.42%
28.81
+81.35%
15.89
+39.13%
11.42
Research And Development
6.80
-68.44%
21.55
+135.35%
9.16
+229.66%
2.78
Selling General And Administration
6.91
-4.82%
7.26
+7.85%
6.73
-22.13%
8.64
General And Administrative Expense
6.91
-4.82%
7.26
+7.85%
6.73
-22.13%
8.64
Salaries And Wages
1.80
+8.32%
1.66
—
—
Other Gand A
5.11
-8.72%
5.60
-16.81%
6.73
-22.13%
8.64
Total Expenses
13.71
-52.42%
28.81
+81.35%
15.89
+39.13%
11.42
Operating Income
-13.71
+52.42%
-28.81
-81.35%
-15.89
-39.13%
-11.42
Total Operating Income As Reported
-13.71
+52.42%
-28.81
-81.35%
-15.89
+19.06%
-19.63
EBITDA
-13.69
+52.45%
-28.79
-81.29%
-15.88
-35.08%
-11.76
Normalized EBITDA
-13.91
+52.16%
-29.09
-54.43%
-18.84
-64.05%
-11.48
Reconciled Depreciation
0.02
-5.00%
0.02
+233.33%
0.01
-70.00%
0.02
EBIT
-13.71
+52.42%
-28.81
-81.35%
-15.89
-34.90%
-11.78
Total Unusual Items
0.23
-24.24%
0.30
-89.95%
2.96
+1174.55%
-0.28
Total Unusual Items Excluding Goodwill
0.23
-24.24%
0.30
-89.95%
2.96
+1174.55%
-0.28
Special Income Charges
—
—
0.00
+100.00%
-8.21
Other Special Charges
—
—
—
8.21
Net Income
-12.97
+52.98%
-27.59
-121.27%
-12.47
+10.72%
-13.97
Pretax Income
-12.97
+52.98%
-27.59
-121.27%
-12.47
+10.72%
-13.97
Net Non Operating Interest Income Expense
0.51
-44.57%
0.92
+99.57%
0.46
+121.04%
-2.19
Interest Expense Non Operating
—
—
0.00
-100.00%
2.19
Net Interest Income
0.51
-44.57%
0.92
+99.57%
0.46
+121.04%
-2.19
Interest Expense
—
—
0.00
-100.00%
2.19
Interest Income Non Operating
0.51
-44.57%
0.92
+99.57%
0.46
0.00
Interest Income
0.51
-44.57%
0.92
+99.57%
0.46
0.00
Other Income Expense
0.23
-24.24%
0.30
-89.95%
2.96
+925.42%
-0.36
Other Non Operating Income Expenses
—
—
—
-0.08
Gain On Sale Of Security
0.23
-24.24%
0.30
-89.95%
2.96
-62.76%
7.93
Tax Provision
0.00
0.00
0.00
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-12.97
+52.98%
-27.59
-121.27%
-12.47
+10.72%
-13.97
Net Income From Continuing Operation Net Minority Interest
-12.97
+52.98%
-27.59
-121.27%
-12.47
+10.72%
-13.97
Net Income From Continuing And Discontinued Operation
-12.97
+52.98%
-27.59
-121.27%
-12.47
+10.72%
-13.97
Net Income Continuous Operations
-12.97
+52.98%
-27.59
-121.27%
-12.47
+10.72%
-13.97
Normalized Income
-13.20
+52.68%
-27.89
-80.80%
-15.43
-12.66%
-13.69
Net Income Common Stockholders
-12.97
+52.98%
-27.59
-121.27%
-12.47
+10.72%
-13.97
Diluted EPS
—
-39.16
-44.72%
-27.06
+94.34%
-477.84
Basic EPS
—
-39.16
-44.72%
-27.06
+94.34%
-477.84
Basic Average Shares
—
0.71
+52.97%
0.46
+1476.37%
0.03
Diluted Average Shares
—
0.71
+52.97%
0.46
+1476.37%
0.03
Diluted NI Availto Com Stockholders
-12.97
+52.98%
-27.59
-121.27%
-12.47
+10.72%
-13.97
Total Other Finance Cost
—
-0.92
-99.57%
-0.46
—
Line Item Trend 2023-12-31
Total Assets
22.78
Current Assets
22.51
Cash Cash Equivalents And Short Term Investments
22.43
Cash And Cash Equivalents
22.43
Cash Financial
22.43
Prepaid Assets
0.08
Current Deferred Assets
—
Other Current Assets
0.08
Total Non Current Assets
0.27
Net PPE
0.25
Gross PPE
0.28
Accumulated Depreciation
-0.03
Machinery Furniture Equipment
0.08
Other Properties
0.20
Other Non Current Assets
0.02
Total Liabilities Net Minority Interest
6.10
Current Liabilities
5.96
Payables And Accrued Expenses
4.95
Payables
1.61
Accounts Payable
0.82
Current Accrued Expenses
3.34
Pensionand Other Post Retirement Benefit Plans Current
0.12
Current Debt And Capital Lease Obligation
0.07
Current Capital Lease Obligation
0.07
Other Current Liabilities
0.82
Total Non Current Liabilities Net Minority Interest
0.14
Long Term Debt And Capital Lease Obligation
0.14
Long Term Capital Lease Obligation
0.14
Stockholders Equity
16.68
Common Stock Equity
16.68
Capital Stock
0.01
Common Stock
0.01
Preferred Stock
0.00
Share Issued
0.45
Ordinary Shares Number
0.45
Treasury Shares Number
0.00
Additional Paid In Capital
124.94
Retained Earnings
-108.27
Gains Losses Not Affecting Retained Earnings
0.00
Other Equity Adjustments
—
Total Equity Gross Minority Interest
16.68
Total Capitalization
16.68
Working Capital
16.55
Invested Capital
16.68
Total Debt
0.20
Capital Lease Obligations
0.20
Net Tangible Assets
16.68
Tangible Book Value
16.68
Dueto Related Parties Current
0.79
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-15.70
+36.46%
-24.71
-128.82%
-10.80
+7.80%
-11.71
Cash Flow From Continuing Operating Activities
-15.70
+36.46%
-24.71
-128.82%
-10.80
+7.80%
-11.71
Net Income From Continuing Operations
-12.97
+52.98%
-27.59
-121.27%
-12.47
+10.72%
-13.97
Depreciation Amortization Depletion
0.02
-5.00%
0.02
+233.33%
0.01
-70.00%
0.02
Depreciation
0.02
-5.00%
0.02
+233.33%
0.01
-70.00%
0.02
Depreciation And Amortization
0.02
-5.00%
0.02
+233.33%
0.01
-70.00%
0.02
Other Non Cash Items
-0.00
-175.00%
0.00
+300.00%
0.00
-99.99%
8.22
Stock Based Compensation
0.41
-23.61%
0.54
+142.34%
0.22
-74.00%
0.85
Operating Gains Losses
-0.23
+24.24%
-0.30
+89.95%
-2.96
+47.87%
-5.67
Gain Loss On Investment Securities
-0.23
+24.24%
-0.30
+89.95%
-2.96
+48.56%
-5.74
Gain Loss On Sale Of PPE
—
—
0.00
-100.00%
0.07
Change In Working Capital
-2.93
-211.96%
2.62
-40.48%
4.40
+476.46%
-1.17
Change In Prepaid Assets
-0.54
-2810.00%
0.02
-71.43%
0.07
+9.38%
0.06
Change In Payables And Accrued Expense
-2.39
-191.95%
2.60
-39.98%
4.33
+451.22%
-1.23
Change In Accrued Expense
0.43
+193.49%
-0.46
-110.94%
4.21
+509.13%
-1.03
Change In Payable
-2.82
-192.18%
3.06
+2606.19%
0.11
+155.94%
-0.20
Change In Account Payable
-2.82
-192.18%
3.06
+2606.19%
0.11
+155.94%
-0.20
Investing Cash Flow
-0.00
+75.00%
-0.01
+84.00%
-0.05
-725.00%
0.01
Cash Flow From Continuing Investing Activities
-0.00
+75.00%
-0.01
+84.00%
-0.05
-725.00%
0.01
Net PPE Purchase And Sale
-0.00
+75.00%
-0.01
+84.00%
-0.05
-725.00%
0.01
Purchase Of PPE
-0.00
+75.00%
-0.01
+84.00%
-0.05
0.00
Sale Of PPE
—
—
0.00
-100.00%
0.01
Capital Expenditure
-0.00
+75.00%
-0.01
+84.00%
-0.05
—
Net Other Investing Changes
—
—
—
—
Financing Cash Flow
9.96
-45.55%
18.30
+22975.00%
-0.08
-100.28%
28.68
Cash Flow From Continuing Financing Activities
9.96
-45.55%
18.30
+22975.00%
-0.08
-100.28%
28.68
Net Common Stock Issuance
11.21
-43.95%
20.00
0.00
-100.00%
32.25
Proceeds From Stock Option Exercised
0.01
+500.00%
0.00
0.00
0.00
Net Other Financing Charges
-1.25
+26.43%
-1.70
-2023.75%
-0.08
+97.76%
-3.57
Changes In Cash
-5.74
+10.58%
-6.42
+41.28%
-10.93
-164.38%
16.98
Effect Of Exchange Rate Changes
—
—
—
0.00
Beginning Cash Position
16.02
-28.61%
22.43
-32.76%
33.36
+103.60%
16.39
End Cash Position
10.28
-35.83%
16.02
-28.61%
22.43
-32.76%
33.36
Free Cash Flow
-15.70
+36.47%
-24.72
-127.84%
-10.85
+7.37%
-11.71
Common Stock Issuance
11.21
-43.95%
20.00
0.00
-100.00%
32.25
Issuance Of Capital Stock
11.21
-43.95%
20.00
0.00
-100.00%
32.25
Net Preferred Stock Issuance
—
—
0.00
-100.00%
32.25
Preferred Stock Issuance
—
—
0.00
-100.00%
32.25
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category